The Apex Times
Above the Noise
Business Wire
BusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex Times
Back to front
Eli Lilly rolls out oral weight-loss and diabetes pill Foundayo in UK pharmacies
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 24, 3:31 AM EDT

Eli Lilly rolls out oral weight-loss and diabetes pill Foundayo in UK pharmacies

The company says its once-daily tablet, marketed for weight management and diabetes, is now available in UK pharmacies as an oral option to injectable GLP-1 therapies.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly and Co has begun selling its once-daily oral weight-management and diabetes pill Foundayo through UK pharmacies, positioning the treatment as an alternative to injectable GLP-1 drugs, according to a report published Tuesday.

The report describes Foundayo as a tablet form of a weight and glucose management therapy and says patients in the UK can obtain it through pharmacies rather than starting with injectable administration.

For Lilly, the UK launch matters because GLP-1 medicines have been largely associated with injections, a delivery method that can affect patient preference, adherence, and the practical pace at which new patients can begin treatment.

An oral option is also likely to broaden the set of patients and prescribers willing to consider a weight-management approach, particularly for those who are reluctant to use injections. That broader accessibility is a theme across the broader obesity and diabetes-drug market, where companies are competing to match both clinical outcomes and day-to-day usability.

Still, the report does not provide detail on how widely the product will be stocked beyond the fact that it is available in pharmacies, nor does it spell out pricing, reimbursement or National Health Service coverage specifics.

It also does not clarify whether the uptake will be limited by supply constraints or by prescriber criteria, or how quickly any initial demand will be met in the UK. Lilly similarly does not describe in the cited report whether Foundayo is being marketed under specific treatment lines for diabetes, weight management, or both, beyond the general description of its purpose.

What to watch next is whether UK prescribing patterns and pharmacy availability expand beyond early supply, and whether Lilly or regulators provide additional guidance on eligibility, coverage, and patient-switching between oral and injectable GLP-1 therapies.

Additional transparency from the company, such as patient-facing information on expected dosing and how Foundayo compares in real-world use to injections, would help define how significant the oral launch is for the broader obesity and diabetes treatment landscape in the UK.

Why It Matters

  • Oral GLP-1-adjacent options could reduce patient friction versus injections, potentially affecting adherence and demand.
  • A UK pharmacy launch can be an early announcement of how quickly oral weight-management therapies may scale in a major European market.
  • The competitive bar is shifting from efficacy alone toward delivery convenience, which can influence prescriber and patient adoption.
  • Near-term market attention will likely focus on how reimbursement, supply, and eligibility shape real-world uptake.

Sources

Key Facts

  • Eli Lilly launched Foundayo in UK pharmacies, according to a report published on Tuesday.
  • Foundayo is described as a once-daily oral pill intended for weight management and diabetes.
  • The launch is positioned as an oral alternative to injectable GLP-1 treatments.
  • The report states patients can access the therapy via UK pharmacies, but does not provide pricing or reimbursement details.
  • The report does not provide information on supply capacity, prescribing criteria, or initial rollout scope beyond pharmacy availability.

Healthcare Related